Genetic and clinical predictors of warfarin dose requirements in African Americans.
about
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Pharmacogenomics of hypertension and heart diseaseWarfarin pharmacogenetics: does more accurate dosing benefit patients?Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysisPharmacology of anticoagulants used in the treatment of venous thromboembolismPharmacogenomics and personalized medicine: a review focused on their application in the Chinese populationEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinWarfarin Pharmacogenetics: New Life for an Old DrugEthnicity-specific pharmacogenetics: the case of warfarin in African AmericansPharmacogenetics of warfarin: challenges and opportunities.Implementing genotype-guided antithrombotic therapy.Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.African American patients with gout: efficacy and safety of febuxostat vs allopurinol.Mapping genes that predict treatment outcome in admixed populationsGenetic and nongenetic factors associated with warfarin dose requirements in Egyptian patientsPharmGKB summary: very important pharmacogene information for CYP4F2Warfarin pharmacogenetics.Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.Genetic warfarin dosing: tables versus algorithms.Clinically relevant genetic variations in drug metabolizing enzymes.Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to AnalysisPharmacogenomics: application to the management of cardiovascular diseaseApolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALURace influences warfarin dose changes associated with genetic factors.A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin.Factors affecting time to maintenance dose in patients initiating warfarin.Genome-wide association study of warfarin maintenance dose in a Brazilian sampleThe Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review.The future of warfarin pharmacogenetics in under-represented minority groups.Warfarin pharmacogenetics: challenges and opportunities for clinical translation.Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patientsImpact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians.Pharmacogenomics of warfarin in populations of African descent.Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium
P2860
Q26823542-DC7F6E30-9329-4892-975A-0A2213BDBCE8Q27015722-575F2765-2B84-45F9-A45D-5C8A1E2ADF3DQ27027304-18EF22C4-5837-47F1-970C-A0C277FF4787Q28071310-004C8757-5B6F-4E0F-A079-80C494D5399BQ28078967-065931BF-B44E-4F40-9CFF-B3CBD56C03B6Q28083875-B020DC1C-79EB-4AFE-9FA9-DF16E7C4A388Q28276514-283103EE-05E0-4D07-B77B-A688A7579133Q28468726-4453222C-EFA4-4960-A409-AC75973989CBQ33591111-CB62507A-D902-4BDB-B4BB-69E3F0A406B5Q33819050-2F1AADC7-AB0C-4513-8A02-799CDA03B4DBQ33990428-2FD73745-2A3B-41C3-92D9-B15A5890AD7DQ34065133-78F65C4B-F54E-4149-BB41-00732D35B090Q34153554-93278932-3014-4BB3-8743-FC9C8F900326Q34348337-B32395F1-F753-4E7B-99E4-95009B431BB9Q34571746-40C05130-949F-4270-A582-516488169438Q34664072-C87E6091-3BEE-4157-BB20-6AC56C3E673FQ34785072-B412BBFB-238E-48A7-A56A-9EC27E0CDD18Q34791041-78F7DE6B-354E-4DDC-BC47-913CFFB51D95Q35021027-CD1313C0-53CF-4E08-A86A-2DA2CC5B7CC2Q35032378-A481FAB8-50E5-4A92-808C-8C1DE1DEE1BCQ35185164-8385E5FF-9592-4DA9-8C29-2644C7ADC106Q35309161-1DA0F0D8-5E94-498A-88CC-D0691DD069FDQ35639536-865C4B87-0815-4B48-A383-1D30428FD24AQ35661209-F258B8C9-A8E1-4279-8354-028D53D06211Q35681000-F4914C02-34FA-46F3-9456-65A24A52B2F6Q35795982-BB01A9CA-FA22-4B24-948B-8E5BB6E19CE0Q35884265-90BBFD89-00EA-49B5-A679-12E8A6E5CBD4Q35888757-6D9BF5D6-78E2-4595-8392-8F4353C4EEBEQ35991881-D38AB236-3437-4769-83B9-C4793F19ECD9Q36015458-AA2D5A45-4E38-4AF2-A23A-4DB74E62CB12Q36060109-B509A3FA-5A89-43E8-9FC0-D410D662D571Q36068687-FFF0DD6A-191B-4810-8BF2-5579AC92B01AQ36228428-B4152460-C361-40D6-A96E-F7A7D0D6A426Q36294461-78009179-635B-424A-9752-8A7E55EA6A99Q36375431-B714D3EA-504C-4B5D-954B-4DD544027C98Q36441521-3BEE5E2B-D4B1-46CB-A5B4-C4E715B19A65Q36511894-93E18232-04F3-4A66-9658-4284D7A77EEBQ36599219-D59EBB2B-A8F3-4399-B598-DC7A80ACD5E8Q36629209-9BB00D28-F81A-4BC2-B49D-42121126FCA1Q36630081-8A89C0B4-21C1-4C22-B040-C66FC65690E9
P2860
Genetic and clinical predictors of warfarin dose requirements in African Americans.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Genetic and clinical predictors of warfarin dose requirements in African Americans.
@en
Genetic and clinical predictors of warfarin dose requirements in African Americans.
@nl
type
label
Genetic and clinical predictors of warfarin dose requirements in African Americans.
@en
Genetic and clinical predictors of warfarin dose requirements in African Americans.
@nl
prefLabel
Genetic and clinical predictors of warfarin dose requirements in African Americans.
@en
Genetic and clinical predictors of warfarin dose requirements in African Americans.
@nl
P2093
P2860
P356
P1476
Genetic and clinical predictors of warfarin dose requirements in African Americans.
@en
P2093
E A Nutescu
J A Johnson
K M Momary
L H Cavallari
M A G Viana
N L Shapiro
T Y Langaee
P2860
P304
P356
10.1038/CLPT.2009.223
P407
P577
2010-01-13T00:00:00Z